SeqOne unlocks the power of Illumina’s TruSightTM Oncology 500
With the addition of the TSO500 pan-cancer NGS assay for genomic profiling of tumour samples, SeqOne now provides oncologists with the most comprehensive genomic data analytics solution for fast, actionable results.
SeqOne offers a powerful genomic analysis platform capable of detecting the complex variants that are critical to cancer diagnosis and treatment.
Get in touch and find out how SeqOne can provide more actionable insights from your genomics data contact@seqone.com.
Similar readings
-
Events News22 September 2023
Genomic data interpretation workshop & lunch seminar in Graz
We will be hosting a workshop & lunch seminar about genomic data interpretation. DATE: November 8th 2023 starting at 10:00, with lunch at 12:00 LOCATION: [...]
-
Events News
11 May 2023
SeqOne at ESHG 2023: A.I. for Diagnostics
We will be hosting a corporate satellite on Monday, June 12, 2023 – 14.00 – 15.30 BST : "Harnessing AI to improve diagnostic yield with [...]
-
News Press release
22 February 2023
SeqOne’s new clinically validated HRD test reduces the number of inconclusive results to improve the prescription of targeted treatments for ovarian cancer patients
The Homologous Recombination Deficiency (HRD) biomarker identifies ovarian cancer patients likely to respond to PARP inhibitors. SeqOne’s test simplifies the deployment of this test while [...]
